Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivo model of deep arterial injury

Thrombosis Research

Volumn 98, Issue 6, 2000, Pages 499-505

  Roqué, Mercè ^a   Rauch, Ursula ^a   Reis, Ernane D ^b   Chesebro, James H ^a   Fuster, Valentin ^a   Badimon, Juan J ^a  

^a Cardiovasc Biol Res Laboratory   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Arterial injury; Low molecular weight heparin; Platelets; Thrombosis

Indexed keywords

FIBRIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; NONHUMAN; PRIORITY JOURNAL; SWINE; THROMBOCYTE; THROMBOGENESIS;

ADENOSINE DIPHOSPHATE; ANIMALS; ARTERIES; BLOOD COAGULATION TESTS; BLOOD FLOW VELOCITY; COLLAGEN; DISEASE MODELS, ANIMAL; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENTS; HEMATOLOGIC TESTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; PERFUSION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; SWINE; THROMBOSIS;

EID: 0034659435     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00202-4     Document Type: Article

References (30)

1. Falk E., Shah P.K., Fuster V. Coronary plaque rupture. Circulation. 92:1995;657-671.
2. Fernandez-Ortiz A., Badimon J.J., Falk E., Fuster V., Meyer B., Mailhac A., Weng D., Shah P.K., Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components. Implications for consequences of plaque rupture J Am Coll Cardiol. 23:1994;1562-1569.
3. Chesebro J.H., Webster M.W.I., Zoldhelyi P., Roche P.C., Badimon L., Badimon J.J. Antithrombotic therapy and progression of coronary artery disease. Circulation. 86(Suppl. III):1992;100-101.
4. Moreno P.R., Bernardi V.H., Lopez-Cuellar J., Murcia A.M., Palacios I.F., Gold H.K., Mehran R., Sharma S.K., Nemerson Y., Fuster V., Fallon J.T. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation. 94:1996;3090-3097.
5. Falk E. Unstable angina with fatal outcome. Dynamic coronary thrombosis leading to infarction and/or sudden death Circulation. 71:1985;699-708.
6. Glagov Z., Zarins C., Giddens D.P., Ku D.N. Hemodynamics and atherosclerosis. Insights and perspectives gained from studies of human arteries. Arch Pathol Lab Med. 112:1988;1018-1031.
7. Fuster V., Falk E., Fallon J.T., Badimon L., Chesebro J.H., Badimon J.J. The three processes leading to post PTCA restenosis. dependence on the lesion substrate Thromb Haemost. 74:1995;552-559.
8. Ewenstein B.M. Antithrombotic agents and thromboembolic disease. N Engl J Med. 337:1997;1383-1384.
9. Weitz J.I. Low-molecular-weight heparins. N Engl J Med. 337:1997;688-698.
10. Turpie A.G.G. Antithrombotic therapy. the expanding role of low molecular weight heparin Indian Heart J. 49:1997;489-492.
11. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M., Kelton J.G. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 332:1995;1330-1335.
12. Cohen M., Demers C., Gurfinkel E.P., Turpie A.G., Fromell G.J., Goodman S., Langer A., Califf R.M., Fox K.A., Premmereur J., Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in non-Q-Wave Coronary Events Study Group. N Engl J Med. 337:1997;447-452.
13. Antman E.M., Cohen M., Radley D., McCabe C., Rush J., Premmereur J., Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 100:1999;1602-1608.
14. 111Indium-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene J Lab Clin Med. 110:1987;706-718.
15. Lassila R., Badimon J.J., Vallabhajosula S., Badimon L. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood. Effects of different stenoses on thrombus growth. Arteriosclerosis. 10:1990;306-315.
16. Meyer B.J., Badimon J.J., Mailhac A., Fernandez-Ortiz A., Chesebro J.H., Fuster V., Badimon L. Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. Circulation. 90:1994;2432-2438.
17. Breddin H.K. Coronary heart disease, unstable angina, PTCA. New indications for low molecular weight heparins? Thromb Res. 81(Suppl.):1996;47-51.
18. Antman E.M., Handin R. Low-molecular-weight heparins. An intriguing new twist with profound implications. Circulation. 98:1998;287-289.
19. Hirsh J., Levine M.N. Low molecular weight heparin. Blood. 79:1992;1-17.
20. Jeske W., Lojewski B., Walenga J.M., Hoppenstaeadt D., Ahsan A., Fareed J. Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin). Semin Thrombosis Hemost. 19:1993;229-240.
21. Fareed J., Jeske W., Eschenfelder V., Iqbal O., Hoppensteadt D., Ahmad A. Preclinical studies on a low molecular weight heparin. Thromb Res. 81(Suppl.):1996;1-27.
22. Karsch K.R., Preisack M.B., Baildon R., Eschenfelder V., Foley D., Garcia E.J., Kaltenbach M., Meisner C., Selbmann H.K., Serruys P.W., Shiu M.F., Sujatta M., Bonan R. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, early administration of reviparin in a double-blind unfractionated heparin and placebo-controlled evaluation. J Am Coll Cardiol. 28:1996;1437-1443.
23. Schoen P., Lindhout T., Franssen J., Hemker H.C. Low molecular weight heparin-catalyzed inactivation of factor Xa and thrombin by antithrombin III. Effect of platelet factor 4. Thromb Haemost. 66:1991;435-441.
24. Kay R., Wong K.S., Yu Y.L., Chan Y.W., Tsoi T.H., Ahuja A.T., Chan F.L., Fong K.Y., Law C.B., Wong A. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 333:1995;1588-1593.
25. Low molecular weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
26. Dolovich L., Ginsberg J.S. Low molecular weight heparin in the treatment of venous thromboembolism. an updated meta-analysis Vessels. 3:1997;4-11.
27. Kakkar V., Cohen A.T., Mohamed M.S. Patients at risk of venous thromboembolism - clinical results with reviparin. Thromb Res. 81(Suppl.):1996;39-45.
28. Merlini P.A., Bauer K.A., Oltrona L., Ardissino D., Cattaneo M., Belli C., Manucci P.M., Rosenberg R.D. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 90:1994;61-68.
29. Chamuleau S.A.J., de Winter R.J., Levi M., Adams R., Buller H.R., Prins M.H., Lie K.I., Peters R.J.G. Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction. The FATIMA study Heart. 80:1998;35-39.
30. Goodman S., Langer A., Demers C., Turpie A., Bigonzi F., Radley D., Le Iouer V., Gosset F., Fromell G., Cohen M. One year follow-up of the ESSENCE trial (enoxaparin vs. heparin in unstable angina/non-Q wave myocardial infarction). Sustained clinical benefit (abstract) Can J Cardiol. 14:1998;122F.